Stability-indicating high performance liquid chromatographic method for simultaneous assay of pibrentasvir and glecaprevir: Method development, validation and application to tablet dosage forms

Satya Venkata Sakuntala Mamidi; Lakshmana Rao Atmakuri; William Carey Mamidipalli

Stability-indicating high performance liquid chromatographic method for simultaneous assay of pibrentasvir and glecaprevir: Method development, validation and application to tablet dosage forms

Abstract

Pibrentasvir and glecaprevir combination therapy acts by inhibiting RNA replication and viron assembly in hepatitis C virus. The aim and objective of the present investigation is to develop and validate a stability indicating RP-HPLC method for simultaneous quantification of pibrentasvir and glecaprevir in bulk and tablets. Pibrentasvir and glecaprevir were separated and analyzed on Agilent Eclipse column (4.6 mm × 150 mm, 5 m). The mobile phase consisted of 0.1% orthophosphoric acid and methanol (30:70, v/v), that was isocratically delivered at a flow rate of 1.0 mL/min. Retention times were 1.857 min for glecaprevir and 2.681 min for pibrentasvir. Good regression coefficients were obtained in range of 50-250 μg/mL for glecaprevir and 20–100 μg/mL for pibrentasvir. The results of validation parameters like selectivity, precision, accuracy and robustness are satisfactory. Tablet sample containing pibrentasvir and glecaprevir was subjected to degradation with 0.1N HCl, 0.1N NaOH, 30% hydrogen peroxide, thermal and photo conditions. The resulting degradants produced during the applied degradation conditions were well resolved from the peaks of pibrentasvir and glecaprevir. The utility of the proposed method was demonstrated by application to tablets containing pibrentasvir and glecaprevir combination. No interference from additives was observed. Therefore the method can be adapted in routine analysis of pibrentasvir and glecaprevir in quality control laboratories. The method can also be used for purity and degradation assessment of pibrentasvir and glecaprevir in tablets.

Keywords

References

[1] Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. [CrossRef]
[2] Bastos JCS, Padilla MA, Caserta LC, Miotto N, Vigani AG, Arns CW. Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol. 2016;22(28):6393–6401. [CrossRef]
[3] World Health Organization. Hepatitis C, WHO fact sheet No. 164, updated July 2015. Available from: [CrossRef]
[4] Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol. 2015;7(10):1377–1389. [CrossRef]
[5] Lamb YN. Glecaprevir/Pibrentasvir: First global approval. Drugs. 2017;77(16):1797–1804. [CrossRef]
[6] Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062–1068. [CrossRef]
[7] Levien TL, Baker DE. Formulary drug reviews: Glecaprevir/Pibrentasvir. Hosp Pharm. 2018;53(2):75–84. [CrossRef]
[8] Aghemo A, Colombo M. Glecaprevir/Pibrentasvir: The final piece in the Hepatitis C virus treatment puzzle? Gastroenterology. 2018;154(4):1195–1196. [CrossRef]

Details

Primary Language

English

Subjects

Basic Pharmacology

Journal Section

Research Article

Authors

Satya Venkata Sakuntala Mamidi ^* This is me
India

Lakshmana Rao Atmakuri This is me
India

William Carey Mamidipalli This is me
India

Publication Date

June 27, 2025

Submission Date

September 20, 2018

Acceptance Date

December 7, 2018

Published in Issue

Year 2019 Volume: 23 Number: 3

IZ

https://izlik.org/JA39TW86ND

Cite

RIS / Bibtex

APA

Mamidi, S. V. S., Atmakuri, L. R., & Mamidipalli, W. C. (2025). Stability-indicating high performance liquid chromatographic method for simultaneous assay of pibrentasvir and glecaprevir: Method development, validation and application to tablet dosage forms. Journal of Research in Pharmacy, 23(3), 465-475. https://izlik.org/JA39TW86ND

AMA

1.Mamidi SVS, Atmakuri LR, Mamidipalli WC. Stability-indicating high performance liquid chromatographic method for simultaneous assay of pibrentasvir and glecaprevir: Method development, validation and application to tablet dosage forms. J. Res. Pharm. 2025;23(3):465-475. https://izlik.org/JA39TW86ND

Chicago

Mamidi, Satya Venkata Sakuntala, Lakshmana Rao Atmakuri, and William Carey Mamidipalli. 2025. “Stability-Indicating High Performance Liquid Chromatographic Method for Simultaneous Assay of Pibrentasvir and Glecaprevir: Method Development, Validation and Application to Tablet Dosage Forms”. Journal of Research in Pharmacy 23 (3): 465-75. https://izlik.org/JA39TW86ND.

EndNote

Mamidi SVS, Atmakuri LR, Mamidipalli WC (June 1, 2025) Stability-indicating high performance liquid chromatographic method for simultaneous assay of pibrentasvir and glecaprevir: Method development, validation and application to tablet dosage forms. Journal of Research in Pharmacy 23 3 465–475.

IEEE

[1]S. V. S. Mamidi, L. R. Atmakuri, and W. C. Mamidipalli, “Stability-indicating high performance liquid chromatographic method for simultaneous assay of pibrentasvir and glecaprevir: Method development, validation and application to tablet dosage forms”, J. Res. Pharm., vol. 23, no. 3, pp. 465–475, June 2025, [Online]. Available: https://izlik.org/JA39TW86ND

ISNAD

Mamidi, Satya Venkata Sakuntala - Atmakuri, Lakshmana Rao - Mamidipalli, William Carey. “Stability-Indicating High Performance Liquid Chromatographic Method for Simultaneous Assay of Pibrentasvir and Glecaprevir: Method Development, Validation and Application to Tablet Dosage Forms”. Journal of Research in Pharmacy 23/3 (June 1, 2025): 465-475. https://izlik.org/JA39TW86ND.

JAMA

1.Mamidi SVS, Atmakuri LR, Mamidipalli WC. Stability-indicating high performance liquid chromatographic method for simultaneous assay of pibrentasvir and glecaprevir: Method development, validation and application to tablet dosage forms. J. Res. Pharm. 2025;23:465–475.

MLA

Mamidi, Satya Venkata Sakuntala, et al. “Stability-Indicating High Performance Liquid Chromatographic Method for Simultaneous Assay of Pibrentasvir and Glecaprevir: Method Development, Validation and Application to Tablet Dosage Forms”. Journal of Research in Pharmacy, vol. 23, no. 3, June 2025, pp. 465-7, https://izlik.org/JA39TW86ND.

Vancouver

1.Satya Venkata Sakuntala Mamidi, Lakshmana Rao Atmakuri, William Carey Mamidipalli. Stability-indicating high performance liquid chromatographic method for simultaneous assay of pibrentasvir and glecaprevir: Method development, validation and application to tablet dosage forms. J. Res. Pharm. [Internet]. 2025 Jun. 1;23(3):465-7. Available from: https://izlik.org/JA39TW86ND